Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05455320 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
A Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 864
- Enrollment target
- 20
- Study locations
NCT05455320 is a Phase 3 study of Relapsed or Refractory Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 864 participants, above the 256-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (238% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05455320, a Phase 3 study of Relapsed or Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 864 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Talquetamab
Study Locations (20)
Massachusetts
- Massachusetts General - Boston
- Boston University Medical Center - Boston
- University of Massachusetts Medical School - Worcester
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
- George Washington University - Washington D.C.
Florida
- Memorial Healthcare System - Hollywood
- University of Miami Health System - Miami
Louisiana
- Tulane University Hospital & Clinics - New Orleans
- Ochsner Health System - New Orleans
Arizona
- The University of Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Norwalk Hospital-oncology - Norwalk
Illinois
- University Of Illinois - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 864 participants |
| Start Date | 2022-10-13 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05455320
The ClinicalTrials.gov registry entry for NCT05455320 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 864 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 256-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (238% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT05455320 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Massachusetts, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT05455320 about?
NCT05455320 is a clinical study titled "A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment". The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (D...
What is the current status of trial NCT05455320?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 864 participants. The study started on 2022-10-13. Estimated completion is 2029-06-30.
What conditions does trial NCT05455320 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05455320?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Talquetamab (DRUG).
Who is sponsoring clinical trial NCT05455320?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05455320 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
RECRUITING · Phase 3
-
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.